nav menu
close nav
background
background

NEWS

19 November 2024

Akston News

Purdue University and Akston Biosciences Bring “First Dose of Hope” in New Cancer Immunotherapy Trial for Dogs with Urinary Bladder Cancer

20 August 2024

Energesis and Akston Biosciences Sign Partnership Agreement for Companion Animal Obesity Drug Development

Energesis and Akston Biosciences Sign Partnership Agreement for Companion Animal Obesity Drug Development

13 August 2024

Purdue and Akston Biosciences Sign Partnership Agreement for Dog Cancer Drug Development

Purdue and Akston Biosciences Sign Partnership Agreement for Dog Cancer Drug Development

30 July 2024

Dechra Purchases Veterinary Insulin Programs from Akston Biosciences

Dechra Purchases Veterinary Insulin Programs from Akston Biosciences

17 June 2024

Dr. Linda Rhodes Joins Akston Biosciences’ Board of Directors

Dr. Linda Rhodes Joins Akston Biosciences’ Board of Directors

13 March 2024

Animal health therapeutic development platform demonstrates versatility

Animal health therapeutic development platform demonstrates versatility

10 March 2024

Akston Biosciences’ AKS-107 Study Published in Frontiers in Immunology, Displaying Ambifect® Platform’s Versatility

Akston Biosciences’ AKS-107 Study Published in Frontiers in Immunology, Displaying Ambifect® Platform’s Versatility

6 March 2024

An antigen-specific immunotherapeutic, AKS-107, deletes insulin-specific B cells and prevents murine autoimmune diabetes

An antigen-specific immunotherapeutic, AKS-107, deletes insulin-specific B cells and prevents murine autoimmune diabetes

26 February 2024

Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine

Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine

26 February 2024

Akston Biosciences’ AKS-452 Vaccine Study Published in Nature, Showcasing Ambifect® Platform’s Versatility

Akston Biosciences’ AKS-452 Vaccine Study Published in Nature, Showcasing Ambifect® Platform’s Versatility